See more : Stratim Cloud Acquisition Corp. (SCAQ) Income Statement Analysis – Financial Results
Complete financial analysis of Cryo-Cell International, Inc. (CCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cryo-Cell International, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Federal Screw Works (FSCR) Income Statement Analysis – Financial Results
- Atrae, Inc. (6194.T) Income Statement Analysis – Financial Results
- Oriental Petroleum and Minerals Corporation (OPTBF) Income Statement Analysis – Financial Results
- HCM II Acquisition Corp. Unit (HONDU) Income Statement Analysis – Financial Results
- Guangdong Huafeng New Energy Technology Co.,Ltd. (002806.SZ) Income Statement Analysis – Financial Results
Cryo-Cell International, Inc. (CCEL)
About Cryo-Cell International, Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.34M | 30.34M | 28.88M | 31.15M | 31.82M | 29.22M | 25.38M | 23.13M | 21.09M | 20.13M | 18.99M | 17.97M | 17.92M | 17.64M | 16.33M | 17.28M | 17.46M | 17.18M | 14.45M | 12.21M | 7.55M | 7.07M | 5.65M | 2.11M | 1.70M | 300.00K | 400.00K | 2.70M |
| Cost of Revenue | 8.44M | 8.79M | 8.99M | 9.66M | 10.04M | 8.54M | 6.72M | 5.77M | 5.63M | 5.63M | 5.32M | 4.89M | 4.40M | 4.50M | 4.53M | 6.11M | 6.59M | 6.07M | 4.14M | 3.16M | 2.63M | 2.50M | 1.66M | 827.33K | 200.00K | 200.00K | 0.00 | 300.00K |
| Gross Profit | 22.90M | 21.54M | 19.90M | 21.49M | 21.78M | 20.68M | 18.66M | 17.35M | 15.46M | 14.49M | 13.67M | 13.08M | 13.52M | 13.13M | 11.79M | 11.16M | 10.87M | 11.11M | 10.31M | 9.05M | 4.92M | 4.58M | 3.99M | 1.28M | 1.50M | 100.00K | 400.00K | 2.40M |
| Gross Profit Ratio | 73.07% | 71.02% | 68.88% | 68.99% | 68.46% | 70.77% | 73.51% | 75.03% | 73.30% | 72.02% | 71.98% | 72.80% | 75.45% | 74.46% | 72.24% | 64.62% | 62.24% | 64.68% | 71.33% | 74.10% | 65.23% | 64.72% | 70.68% | 60.78% | 88.24% | 33.33% | 100.00% | 88.89% |
| Research & Development | 1.17M | 384.79K | 49.87K | 23.85K | 30.15K | 91.85K | 41.17K | 53.10K | 45.78K | 64.37K | 36.17K | 109.64K | 184.05K | 132.99K | 102.41K | 194.46K | 545.49K | 486.16K | 26.15K | 82.51K | 226.68K | 219.66K | 51.07K | 275.80K | 100.00K | 400.00K | 200.00K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.63M | 13.48M | 14.72M | 12.39M | 12.25M | 11.37M | 14.43M | 12.41M | 9.49M | 8.94M | 10.83M | 14.46M | 12.96M | 9.10M | 6.27M | 9.71M | 6.06M | 3.95M | 2.85M | 2.30M | 1.90M | 1.80M | 1.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.12M | 15.58M | 14.63M | 14.29M | 14.89M | 15.63M | 13.48M | 14.72M | 12.39M | 12.25M | 11.37M | 14.43M | 12.41M | 9.49M | 8.94M | 10.83M | 14.46M | 12.96M | 9.10M | 6.27M | 9.71M | 6.06M | 3.95M | 2.85M | 2.30M | 1.90M | 1.80M | 1.50M |
| Other Expenses | 16.92M | 1.12M | 834.85K | 166.44K | 206.24K | -24.72K | -79.87K | -14.67K | 22.99K | 210.26K | 48.85K | 204.15K | 571.41K | 294.06K | 1.08M | 408.77K | 532.31K | 629.15K | -45.87K | -488.89K | 2.51M | 3.84M | 476.48K | 313.49K | 100.00K | 200.00K | 100.00K | 100.00K |
| Operating Expenses | 35.21M | 17.08M | 15.51M | 14.48M | 15.13M | 15.90M | 13.65M | 14.93M | 12.53M | 12.49M | 11.59M | 14.74M | 13.17M | 9.91M | 10.12M | 11.43M | 15.54M | 14.07M | 9.08M | 5.87M | 12.45M | 10.12M | 4.48M | 3.44M | 2.50M | 2.50M | 2.10M | 1.60M |
| Cost & Expenses | 43.65M | 25.88M | 24.50M | 24.14M | 25.16M | 24.44M | 20.38M | 20.71M | 18.16M | 18.12M | 16.91M | 19.63M | 17.57M | 14.42M | 14.65M | 17.54M | 22.13M | 20.14M | 13.23M | 9.03M | 15.07M | 12.61M | 6.13M | 4.27M | 2.70M | 2.70M | 2.10M | 1.90M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.91K | 26.30K | 71.64K | 154.82K | 318.01K | 322.37K | 143.50K | 47.51K | 53.24K | 128.27K | 110.77K | 121.84K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.24M | 1.52M | 1.38M | 1.54M | 1.70M | 1.55M | 1.30M | 947.34K | 1.30M | 1.15M | 1.40M | 1.02M | 1.46M | 1.28M | 1.42M | 1.32M | 1.39M | 1.02M | 863.71K | 750.13K | 655.73K | 58.85K | 10.48K | 2.21K | 0.00 | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 1.81M | 1.33M | 635.98K | 401.31K | 317.33K | 230.00K | 286.65K | 241.21K | 377.01K | 394.50K | 466.74K | 579.85K | 580.19K | 671.82K | 678.15K | 741.77K | 724.52K | 597.37K | 657.38K | 452.58K | 802.45K | 512.63K | 313.49K | 100.00K | 200.00K | 100.00K | 100.00K |
| EBITDA | -10.42M | 6.65M | 5.32M | 7.22M | 5.50M | 5.48M | 5.16M | -1.25M | 2.49M | 2.21M | 1.99M | -1.35M | 112.99K | 3.65M | 3.63M | 1.38M | -3.93M | -2.24M | 1.82M | 3.84M | -6.33M | -5.16M | 26.74K | -1.85M | -900.00K | -2.00M | -1.40M | 900.00K |
| EBITDA Ratio | -33.24% | 20.67% | 19.77% | 24.54% | 22.27% | 17.34% | 20.31% | 11.65% | 15.07% | 11.09% | 12.48% | -7.49% | 5.40% | 20.67% | 22.26% | 2.33% | -28.02% | -17.54% | 4.91% | 17.91% | -77.69% | -29.74% | -20.91% | -113.70% | -82.35% | -733.33% | -425.00% | 37.04% |
| Operating Income | -12.30M | 4.02M | 4.00M | 7.66M | 5.06M | 5.19M | 5.01M | 433.59K | 2.93M | 1.98M | 1.70M | -1.71M | -276.74K | 3.22M | 1.67M | -326.75K | -4.67M | -2.96M | 1.22M | 3.18M | -7.52M | -5.54M | -485.89K | -2.16M | -1.00M | -2.40M | -1.70M | 800.00K |
| Operating Income Ratio | -39.26% | 13.27% | 13.86% | 24.60% | 15.91% | 17.76% | 19.72% | 1.87% | 13.91% | 9.84% | 8.96% | -9.52% | -1.54% | 18.27% | 10.24% | -1.89% | -26.76% | -17.23% | 8.47% | 26.04% | -99.64% | -78.28% | -8.60% | -102.45% | -58.82% | -800.00% | -425.00% | 29.63% |
| Total Other Income/Expenses | -1.06M | -705.52K | -1.41M | -2.62M | -1.67M | -1.57M | -1.38M | -2.91M | -1.98M | -1.30M | -1.51M | -2.71M | -1.65M | -1.38M | -1.46M | -294.33K | -332.75K | 232.98K | -106.79K | -160.71K | -739.11K | -349.48K | 485.89K | 550.75K | 500.00K | 0.00 | 100.00K | -100.00K |
| Income Before Tax | -13.36M | 3.32M | 2.61M | 5.04M | 3.39M | 3.62M | 3.62M | -2.48M | 949.52K | 677.15K | 197.02K | -4.42M | -1.70M | 1.78M | 1.55M | -760.42K | -5.01M | -2.73M | 1.12M | 3.02M | -7.52M | -5.17M | 775.95K | -1.61M | -500.00K | 0.00 | -1.60M | 700.00K |
| Income Before Tax Ratio | -42.64% | 10.94% | 9.04% | 16.18% | 10.66% | 12.38% | 14.28% | -10.72% | 4.50% | 3.36% | 1.04% | -24.60% | -9.47% | 10.09% | 9.47% | -4.40% | -28.67% | -15.87% | 7.73% | 24.72% | -99.62% | -73.04% | 13.74% | -76.34% | -29.41% | 0.00% | -400.00% | 25.93% |
| Income Tax Expense | -3.84M | 547.54K | 527.71K | 1.41M | 1.10M | 4.47M | 1.31M | -1.16M | -7.16M | 123.53K | 169.58K | 1.89M | 171.94K | -1.63M | 121.81K | 494.41K | 332.75K | -148.70K | -36.00K | 86.00K | 1.10K | 161.50K | -1.39M | -670.37K | -400.00K | -100.00K | -100.00K | 200.00K |
| Net Income | -9.52M | 2.77M | 2.08M | 3.62M | 2.29M | -854.82K | 2.32M | -1.32M | 8.11M | 553.62K | 27.44K | -6.31M | -2.10M | 3.41M | 1.42M | -760.42K | -5.01M | -2.81M | 1.03M | 2.84M | -7.52M | -5.33M | 899.63K | -1.49M | -600.00K | -2.30M | -1.60M | 600.00K |
| Net Income Ratio | -30.38% | 9.14% | 7.21% | 11.64% | 7.20% | -2.93% | 9.12% | -5.71% | 38.43% | 2.75% | 0.14% | -35.11% | -11.69% | 19.34% | 8.73% | -4.40% | -28.67% | -16.36% | 7.15% | 23.26% | -99.63% | -75.32% | 15.93% | -70.67% | -35.29% | -766.67% | -400.00% | 22.22% |
| EPS | -1.14 | 0.33 | 0.26 | 0.48 | 0.29 | -0.11 | 0.33 | -0.16 | 0.85 | 0.05 | 0.00 | -0.56 | -0.18 | 0.29 | 0.12 | -0.06 | -0.43 | -0.24 | 0.09 | 0.25 | -0.66 | -0.47 | 0.09 | -0.15 | -0.07 | -0.32 | -0.23 | 0.09 |
| EPS Diluted | -1.14 | 0.33 | 0.25 | 0.45 | 0.27 | -0.11 | 0.30 | -0.16 | 0.83 | 0.05 | 0.00 | -0.56 | -0.18 | 0.29 | 0.12 | -0.06 | -0.43 | -0.24 | 0.08 | 0.24 | -0.66 | -0.47 | 0.09 | -0.15 | -0.07 | -0.32 | -0.23 | 0.09 |
| Weighted Avg Shares Out | 8.34M | 8.47M | 8.14M | 8.14M | 8.41M | 7.46M | 7.06M | 8.11M | 9.54M | 10.18M | 10.86M | 11.31M | 11.76M | 11.75M | 11.75M | 11.73M | 11.66M | 11.62M | 11.58M | 11.37M | 11.35M | 11.34M | 10.58M | 9.76M | 8.21M | 7.28M | 6.96M | 7.18M |
| Weighted Avg Shares Out (Dil) | 8.34M | 8.48M | 8.36M | 8.14M | 8.41M | 7.46M | 7.65M | 8.11M | 9.80M | 10.43M | 10.97M | 11.31M | 11.76M | 11.81M | 11.80M | 11.73M | 11.66M | 11.62M | 12.23M | 11.91M | 11.35M | 11.34M | 10.58M | 9.76M | 8.21M | 7.28M | 6.96M | 7.18M |
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2024 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2024. Financial Results...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024. Financial Results...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023. Financial Results...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023. Financial Results Revenue...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2023 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2023. Financial Results...
Cryo-Cell International: A Stable Business Paired With An Upcoming Catalyst
Cryo-Cell International has a stable business that generates consistent cash flow. The company is close to monetizing a partnership with Duke University to bring patented stem cell treatments to market.
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2021 Financial Results
OLDSMAR, Fla., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third...
Cryo-Cell International Announces Changes To Its Board of Directors
MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (Nasdaq:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi to the Company's Board of Directors, replacing Mr....
Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market
Cryo-Cell International, Inc. (Symbol CCEL), The Leader In Cord Blood And Cord Tissue Cryopreservation Services, Today Announced That The Company's Common Stock Has Been Approved For Listing On The Nasdaq Capital Market (“Nasdaq”).
Cryo-Cell International Completes Acquisition of Real Estate Property for Its Institute for Cellular Therapies
Cryo-Cell International (symbol: CCEL) Purchases Real Estate Location for its Institute for Cellular Therapies in the Raleigh-Durham area.
Source: https://incomestatements.info
Category: Stock Reports